TABLE OF CONTENTS
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. ForecastingTechniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL MORPHINE MARKET, BY DOSAGE FORM
6.1. Overview
6.2. Injection
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.3. Oral
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
6.4. Other Dosage Forms
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7. GLOBAL MORPHINE MARKET, BY APPLICATION
7.1. Overview
7.2. Pain Management
7.2.1. Cancer Pain
7.2.2. Neuropathic Pain
7.2.3. Osteoarthritis Pain
7.2.4. Other Pain Management
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.3. Diarrhea Suppressant
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.4. Cold and Cough Suppressant
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
7.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8. GLOBAL MORPHINE MARKET, BY END USER
8.1. Overview
8.2. Hospitals& Clinics
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8.3. Ambulatory Surgical Centres
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
8.4. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9. GLOBAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL
9.1. Overview
9.2. Hospital Pharmacies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.3. Retail Pharmacies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.4. Online Pharmacies
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
9.5. Others
Market Estimates & Forecast, by Region, 2022–2030
Market Estimates & Forecast, by Country, 2022–2030
10. GLOBAL MORPHINE MARKET, BY REGION
10.1. Overview
10.2. North America
10.2.1. US
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. Italy
10.3.4. Spain
10.3.5. UK
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Rest of the World
10.5.1. Middle East
10.5.2. Africa
10.5.3. Latin America
11. COMPANY LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Morphine Market
11.5. Competitive Benchmarking
11.6. Leading Players in terms of Number of Developments in the Global Morphine Market
11.7. Key developments and Growth Strategies
11.7.1. New ProductLaunch/Service Deployment
11.7.2. Merger &Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2020
11.8.2. Major Players R&D Expenditure, 2020
12. COMPANY PROFILES
12.1. Mallinckrodt Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Offered
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Alcaliber
12.2.1. Company Overview
12.2.2. Products Offered
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Purdue Pharma
12.3.1. Company Overview
12.3.2. Products Offered
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Sanofi Winthrop Industrie
12.4.1. Company Overview
12.4.2. Products Offered
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Macfarlan Smith
12.5.1. Company Overview
12.5.2. Products Offered
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Sun Pharmaceutical Industries
12.6.1. Company Overview
12.6.2. Products Offered
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Qinghai Pharmaceutical
12.7.1. Company Overview
12.7.2. Products Offered
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Northeast Pharmaceutical Group
12.8.1. Company Overview
12.8.2. Products Offered
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Products Offered
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Verve Health Care Ltd.
12.10.1. Company Overview
12.10.2. Products Offered
12.10.3. Financial Overview
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Johnson Matthey Fine Chemicals
12.11.1. Company Overview
12.11.2. Products Offered
12.11.3. Financial Overview
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Manus Aktteva Biopharma LLP
12.12.1. Company Overview
12.12.2. Products Offered
12.12.3. Financial Overview
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
12.13. Mayne Pharma Group Limited
12.13.1. Company Overview
12.13.2. Products Offered
12.13.3. Financial Overview
12.13.4. Key Developments
12.13.5. SWOT Analysis
12.13.6. Key Strategies
12.14. Daiichi Sankyo Inc.
12.14.1. Company Overview
12.14.2. Products Offered
12.14.3. Financial Overview
12.14.4. Key Developments
12.14.5. SWOT Analysis
12.14.6. Key Strategies
12.15. Taj Pharmaceuticals Limited
12.15.1. Company Overview
12.15.2. Products Offered
12.15.3. Financial Overview
12.15.4. Key Developments
12.15.5. SWOT Analysis
12.15.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL MORPHINE MARKET SYNOPSIS, 2022–2030
TABLE 2 GLOBAL MORPHINE MARKET ESTIMATES &FORECAST, 2022–2030 (USD MILLION)
TABLE 3 GLOBAL MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 4 GLOBAL MORPHINE MARKET, BY APPLICATION,2022–2030 (USD MILLION)
TABLE 5 GLOBAL MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 6 GLOBAL MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 7 NORTH AMERICA: MORPHINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 8 NORTH AMERICA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 9 NORTH AMERICA MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 10 NORTH AMERICA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 11 NORTH AMERICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 12 US: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 13 US MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 14 US: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 15 US: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 16 CANADA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 17 CANADA MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 18 CANADA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 19 CANADA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 20 EUROPE: MORPHINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 21 EUROPE: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 22 EUROPE: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 23 EUROPE: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 24 EUROPE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 25 GERMANY: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 26 GERMANY: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 27 GERMANY: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 28 GERMANY: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 29 FRANCE: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 30 FRANCE: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 31 FRANCE: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 32 FRANCE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 33 ITALY: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 34 ITALY: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 35 ITALY: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 36 ITALY: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 37 SPAIN: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 38 SPAIN: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 39 SPAIN: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 40 SPAIN: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 41 UK: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 42 UK: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 43 UK: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 44 UK: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 45 REST OF EUROPE: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 46 REST OF EUROPE: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 47 REST OF EUROPE: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 48 REST OF EUROPE: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC: MORPHINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 54 JAPAN: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 55 JAPAN: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 56 JAPAN: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 57 JAPAN: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 58 CHINA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 59 CHINA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 60 CHINA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 61 CHINA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 62 INDIA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 63 INDIA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 64 INDIA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 65 INDIA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 66 AUSTRALIA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 67 AUSTRALIA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 68 AUSTRALIA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 69 AUSTRALIA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 70 SOUTH KOREA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 71 SOUTH KOREA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 72 SOUTH KOREA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 73 SOUTH KOREA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 74 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 75 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 76 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 77 REST OF ASIA-PACIFIC: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 78 REST OF THE WORLD: MORPHINE MARKET, BY REGION, 2022–2030 (USD MILLION)
TABLE 79 REST OF THE WORLD: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 80 REST OF THE WORLD: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 81 REST OF THE WORLD: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 82 REST OF THE WORLD: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 83 MIDDLE EAST: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 84 MIDDLE EAST: MORPHINE MARKET,BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 85 MIDDLE EAST: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 86 MIDDLE EAST: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 87 AFRICA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 88 AFRICA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 89 AFRICA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 90 AFRICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
TABLE 91 LATIN AMERICA: MORPHINE MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION)
TABLE 92 LATIN AMERICA: MORPHINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
TABLE 93 LATIN AMERICA: MORPHINE MARKET, BY END USER, 2022–2030 (USD MILLION)
TABLE 94 LATIN AMERICA: MORPHINE MARKET, BY DISTRIBUTION CHANNEL, 2022–2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MORPHINE MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MORPHINE MARKET
FIGURE 4 GLOBAL MORPHINE MARKET SHARE, BY DOSAGE FORM, 2020 (%)
FIGURE 5 GLOBAL MORPHINE MARKET SHARE, BY APPLICATION, 2020(%)
FIGURE 6 GLOBAL MORPHINE MARKET SHARE, BY END USER, 2020(%)
FIGURE 7 GLOBAL MORPHINE MARKET SHARE, BYDISTRIBUTION CHANNEL, 2020 (%)
FIGURE 8 GLOBAL MORPHINE MARKET SHARE, BY REGION, 2020(%)
FIGURE 9 NORTH AMERICA: MORPHINE MARKET SHARE, BY REGION, 2020(%)
FIGURE 10 EUROPE: MORPHINE MARKET SHARE, BY REGION, 2020(%)
FIGURE 11 ASIA-PACIFIC: MORPHINE MARKET SHARE, BY REGION, 2020(%)
FIGURE 12 REST OF THE WORLD: MORPHINE MARKET SHARE, BY REGION, 2020(%)
FIGURE 13 GLOBAL MORPHINE MARKET: COMPANY SHARE ANALYSIS, 2020(%)
FIGURE 14 MALLINCKRODT PHARMACEUTICALS: KEY FINANCIALS
FIGURE 15 MALLINCKRODT PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 16 MALLINCKRODT PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 17 ALCALIBER: KEY FINANCIALS
FIGURE 18 ALCALIBER: SEGMENTAL REVENUE
FIGURE 19 ALCALIBER: REGIONAL REVENUE
FIGURE 20 PURDUE PHARMA: KEY FINANCIALS
FIGURE 21 PURDUE PHARMA: SEGMENTAL REVENUE
FIGURE 22 PURDUE PHARMA: REGIONAL REVENUE
FIGURE 23 SANOFI WINTHROP INDUSTRIE: KEY FINANCIALS
FIGURE 24 SANOFI WINTHROP INDUSTRIE: SEGMENTAL REVENUE
FIGURE 25 SANOFI WINTHROP INDUSTRIE: REGIONAL REVENUE
FIGURE 26 MACFARLAN SMITH: KEY FINANCIALS
FIGURE 27 MACFARLAN SMITH: SEGMENTAL REVENUE
FIGURE 28 MACFARLAN SMITH: REGIONAL REVENUE
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES: KEY FINANCIALS
FIGURE 30 SUN PHARMACEUTICAL INDUSTRIES: SEGMENTAL REVENUE
FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES: REGIONAL REVENUE
FIGURE 32 QINGHAI PHARMACEUTICAL: KEY FINANCIALS
FIGURE 33 QINGHAI PHARMACEUTICAL: SEGMENTAL REVENUE
FIGURE 34 QINGHAI PHARMACEUTICAL: REGIONAL REVENUE
FIGURE 35 NORTHEAST PHARMACEUTICAL GROUP: KEY FINANCIALS
FIGURE 36 NORTHEAST PHARMACEUTICAL GROUP: SEGMENTAL REVENUE
FIGURE 37 NORTHEAST PHARMACEUTICAL GROUP: REGIONAL REVENUE
FIGURE 38 PFIZER INC.: KEY FINANCIALS
FIGURE 39 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 40 PFIZER INC.: REGIONAL REVENUE
FIGURE 41 VERVE HEALTH CARE LTD.: KEY FINANCIALS
FIGURE 42 VERVE HEALTH CARE LTD.: SEGMENTAL REVENUE
FIGURE 43 VERVE HEALTH CARE LTD.: REGIONAL REVENUE
FIGURE 44 JOHNSON MATTHEY FINE CHEMICALS: KEY FINANCIALS
FIGURE 45 JOHNSON MATTHEY FINE CHEMICALS: SEGMENTAL REVENUE
FIGURE 46 JOHNSON MATTHEY FINE CHEMICALS: REGIONAL REVENUE
FIGURE 47 MANUS AKTTEVA BIOPHARMA LLP: KEY FINANCIALS
FIGURE 48 MANUS AKTTEVA BIOPHARMA LLP: SEGMENTAL REVENUE
FIGURE 49 MANUS AKTTEVA BIOPHARMA LLP: REGIONAL REVENUE
FIGURE 50 MAYNE PHARMA GROUP LIMITED: KEY FINANCIALS
FIGURE 51 MAYNE PHARMA GROUP LIMITED: SEGMENTAL REVENUE
FIGURE 52 MAYNE PHARMA GROUP LIMITED: REGIONAL REVENUE
FIGURE 53 DAIICHI SANKYO INC.: KEY FINANCIALS
FIGURE 54 DAIICHI SANKYO INC.: SEGMENTAL REVENUE
FIGURE 55 DAIICHI SANKYO INC.: REGIONAL REVENUE
FIGURE 56 TAJ PHARMACEUTICALS LIMITED: KEY FINANCIALS
FIGURE 57 TAJ PHARMACEUTICALS LIMITED: SEGMENTAL REVENUE
FIGURE 58 TAJ PHARMACEUTICALS LIMITED: REGIONAL REVENUE
